| Ytd | 6.29% | |
| 1y | 712.96% |
| Open | 105.84 | Prev Close | 104.49 | Low | 102.72 | High | 106.22 | Mkt Cap | 5.17B |
| Vol | 120.20K | Avg Vol | 1.33M | EPS | -3.90 | P/E | N/A | Forward P/E | 141.20 |
| Beta | 0.12 | Short Ratio | 6.18 | Inst. Own | 101.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 114.24 | 200-d Avg | 99.02 | 1yr Est | 160.64 |
CELC News
Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcr
Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechn
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Comp
Craig-Hallum analyst Alexander Nowak maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the p
Wells Fargo analyst Eva Fortea Verdejo maintains Celcuity (NASDAQ:CELC) with a Overweight and low
Celcuity (CELC) shares dropped over 25% despite Phase 3 VIKTORIA-1 data confirming gedatolisib's bes
Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrad
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Bu
Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechn
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Comp
Celcuity Inc. (CELC) Discusses VIKTORIA-1 Trial Results for PIK3CA Mutant Advanced Breast Cancer and
Celcuity Inc. (NASDAQ:CELC) on Tuesday reported detailed efficacy and safety findings from the PIK3C
Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-muta
Celcuity shares slumped 25% , set for their biggest one-day decline, on Tuesday after its experiment
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of ta
MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biote
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of ta
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of ta
MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotec
MINNEAPOLIS, May 28, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotech
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Bu
On Thursday, Celcuity Inc. (NASDAQ:CELC) announced amendments to its Phase 3 VIKTORIA-2 clinical tri
Celcuity expands VIKTORIA-2 to endocrine-sensitive breast cancer patients and advances injectable ge
Wells Fargo analyst Eva Fortea Verdejo maintains Celcuity (NASDAQ:CELC) with a Overweight and rai
Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
Celcuity NASDAQ: CELC reported a wider first-quarter loss as the biotechnology company increased spe
Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.86) per share which beat the analyst consens
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotech
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of t
Development of a gedatolisib formulation for subcutaneous injection is underway; first patent applic
MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotech
Citizens analyst Silvan Turkcan maintains Celcuity (NASDAQ:CELC) with a Market Outperform and rai
Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af
Wall Street analysts changed outlook on top names, including PRU, ARE, TRGP, VITL, and GOOGL. See an
Guggenheim analyst Brad Canino maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price t
Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, includ
Wall Street analysts upgraded and raised price targets for ESS, SITE, PKG, ABNB, and CELC. See what
Needham analyst Rick Patel maintained a Buy rating. Steven Madden shares closed at $47.27 on Friday.
HC Wainwright & Co. analyst Swayampakula Ramakanth upgrades Celcuity (NASDAQ:CELC) from Neutr
Celcuity Inc. (NASDAQ:CELC) shares are up during Monday's premarket session following positive news
Celcuity stock rises after Phase 3 VIKTORIA-1 trial meets endpoint, showing PFS gains in breast canc
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target
eBay (NASDAQ: EBAY) rose sharply after GameStop (NYSE: GME) proposed to acquire it for $125/share, v
Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted
Detailed data for the gedatolisib triplet and doublet regimens will be presented at a late-breaking
Citizens analyst Silvan Turkcan initiates coverage on Celcuity (NASDAQ:CELC) with a Market Outper